BACKGROUND Brugada syndrome (BrS) is a sudden death-predisposing genetic condition characterized electrocardiographically by ST segment elevation in the leads V 1 -V 3 . Given the prominent role of the transient outward current (I to ) in BrS pathogenesis, we hypothesized that rare gain-of-function mutations in KCND3 may serve as a pathogenic substrate for BrS.
Introduction
Sudden cardiac death (SCD) accounts for approximately 300,000 deaths in the United States annually. 1 While structural heart disease represents the primary etiology of SCD in the general population, it is estimated that as many as one-third of young cases and 5%-10% of all SCDs occur 15, 2011.) within individuals with no detectable structural abnormalities upon postmortem investigation. 2, 3 Tragically, thousands of individuals under the age of 40 with otherwise structurally normal hearts die suddenly each year, representing a loss of life-years that rivals ischemic-related heart disease. 2, 4 Cardiac channelopathies such as catecholaminergic polymorphic ventricular tachycardia, long QT syndrome (LQTS), and Brugada syndrome (BrS), which arise from heritable defects in cardiac ion channel function, represent the most common identifiable causes underlying autopsynegative sudden unexplained death. 5 BrS affects as many as 1 in 2,500 individuals and is characterized electrocardiographically by dynamic covedtype ST segment elevation in the right precordial leads in the absence of ischemia, structural heart disease, and pharmacologic agents known to induce a BrS-like electrocardiogram (ECG) pattern. 6, 7 Affected individuals are typically males in the fourth decade of life with a high incidence of syncope and sudden death secondary to ventricular arrhythmias that often develop during times of increased vagal activity such as sleep or rest. Owing to the variable penetrance and expressivity of this autosomal-dominant disorder, the clinical course of BrS assumes a spectrum that includes lifelong asymptomatic individuals as well as those who die suddenly in early life, including infancy. 8 It is estimated that BrS accounts for nearly 5% of all sudden deaths and up to 20% of sudden deaths in individuals with otherwise structurally normal hearts. 7 Since its seminal description as a clinical entity in 1992, BrS has been linked to mutations in genes that perturb cardiac sodium (I Na ), calcium (I Ca.L ), or potassium (I to and I K-ATP ) channel function. At the cellular and ionic level, insufficient sodium (I Na ) or calcium (I Ca ) inward depolarizing current coupled with a right ventricular (RV) transmural gradient (epicardium Ͼ endocardium) involving the transient outward repolarizing current (I to ) conducted by the KCND3-encoded Kv4.3 ␣-subunit is hypothesized to result in an outward shift in current, heterogenous loss of the action potential (AP) dome, ST segment elevation on ECG, local reexcitation via phase II reentry, and the initiation of polymorphic ventricular tachycardia or ventricular fibrillation. 9 The recent identification of (1) a BrS-associated lossof-function missense mutation in the negative modulating KCNE3-encoded MiRP2 Kv4.3 ␤-subunit 10 that significantly increases I to current and (2) a J-wave syndromeassociated pleiotropic gain-of-function missense mutation in the KCNJ8-encoded Kir6.1 ␣-subunit of the ATP-sensitive potassium (I K-ATP ) channel 11 have strengthened the hypothesis that a gain-of-function in outward potassium currents (I to and I K-ATP ) active during early repolarization can contribute to the pathogenesis of BrS and other disorders of early repolarization. Despite major advances in the understanding of the cellular, ionic, and genetic basis of BrS, an estimated 60%-70% of BrS cases remain genetically elusive.
Even though no mutations in the KCND3-encoded Kv4.3 channel have been identified to date, we hypothesized that rare gain-of-function mutations in KCND3 may confer risk for lethal ventricular arrhythmias and thus may serve as the pathogenic substrate for some genetically elusive cases of BrS. In this study, we sought to determine the spectrum and prevalence of KCND3 mutations in a cohort of 86 BrS patients previously screened for mutations in BrS1-BrS8 with spontaneous or flecainide-induced ST segment elevation in the right precordial leads in the absence of any structural or ischemic heart disease by echocardiogram and coronary angiogram.
Methods

Study population
The study population consisted of 86 unrelated patients diagnosed with BrS on established clinical criteria who were referred to the Windland Smith Rice Sudden Death Genomics Laboratory at Mayo Clinic, Rochester, Minnesota, or the Molecular Cardiology Laboratory, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, for laboratorybased genetic testing. All BrS cases included in this study were screened previously for mutations in the eight known BrS-susceptibility genes (SCN5A, GPD1L, CACNA1C, CACNB2, SCN1B, KCNE3, SCN3B, and KCNJ8).
This study was approved by both the Mayo Foundation Institutional Review Board and the Medical Ethical Committee of Fondazione IRCCS Policlinico San Matteo. Informed consent was obtained for all patients.
Control population
DNA from a cohort of 780 (680 Caucasian and 100 African American) ostensibly healthy individuals was obtained from the Coriel Cell Repository and the European Collection of Cell Cultures. These samples were used to assess allelic frequency for all identified nonsynonymous variants and to independently determine the rate of background genetic variation within KCND3 among healthy blood donors.
Mutational analysis
Genomic DNA was extracted from peripheral blood lymphocytes using Purgene DNA extraction kits (Gentra Systems Inc., Minneapolis, MN). Comprehensive mutational analysis of KCND3 was accomplished in cases and controls using polymerase chain reaction (PCR), denaturing highperformance liquid chromatography (DHPLC), and direct DNA sequencing as described elsewhere. 12 The flanking primers used to amplify KCND3 were designed using the Primer3 Web-based interface. 13 Primer sequences, PCR conditions, and DHPLC conditions are available upon request.
KCND3 and KCNIP2 mammalian expression vectors and mutagenesis
Wild-type human KCND3 cDNA was provided by Charles Antzelevitch. The wild-type human KCNIP2 cardiac isoform cDNA was synthesized as a custom minigene con- WTdsRed2 using 5 L of lipofectamine transfection reagent (Invitrogen, Carlsbad, CA) in Gibco OPTI-MEM media (Invitrogen). Cells exhibiting both green fluorescence (excitation 488 nm, emission 507 nm) and red fluorescence (excitation 558 nm, emission 583 nm) at 24 hours posttransfection were selected for electrophysiological experiments.
Electrophysiological measurements and data analysis
The standard whole-cell patch clamp technique was used to measure Kv4.3-WT, Kv4.3-L450F, or Kv4.3-G600R plus KChIP2-WT currents at room temperature (22-24°C) with the use of an Axopatch 200B amplifier, Digidata 1440A, and pClamp version 10.2 software (Axon Instruments, Foster City, CA). The extracellular (bath) solution contained (mmol/L) 140 NaCl, 4 KCl, 2 CaCl 2 , 1 MgCl 2, and 10 HEPES, pH adjusted to 7.4 with NaOH. The pipette solution contained (mmol/L) 110 KCl, 31 KOH, 10 EDTA, 5.17 CaCl 2, 1.42 MgCl 2, 4 MgATP, and 10 HEPES, pH adjusted to 7.2 with KOH following established protocols. 10, 14 Microelectrodes were pulled on a P-97 puller (Sutter Instruments, Novato, CA) and fire polished to a final resistance of 2-3 M⍀. Series resistance was compensated by 80%-85%. Currents were filtered at 5 kHz and digitized at 10 kHz. The voltage-dependence of activation, inactivation, and recovery from inactivation were determined using voltage-clamp protocols described in the figure legends and insets for 
Simulated ventricular epicardial APs
RV and left ventricular (LV) epicardial APs were simulated using a Luo-Rudy II multicellular one-dimensional fiber AP model, modified to include the I to current, as described elsewhere. 15, 16 The incorporation of I to in the Luo-Rudy II AP model requires decreasing maximal conductance of I CaL by 20% to compensate for the significant increase of I CaL during the notch of the AP. The maximal conductance of RV I to was set to 1.3 mS/F for wild type, 2.32 mS/F for L450F, and 1.56 mS/F for G600R in accordance with experimentally derived values across the 0 to ϩ40 mV range that reflect the assumption that heterozygous expression of L450F and G600R in the heart results in at least a 50% reduction in the observed I to gain of function. The time constant of inactivation of the G600R mutant was increased by 19% in agreement with experimental data.
Statistical analysis
All data points represent the mean value, and bars represent the standard error of the mean (SEM). Determination of statistical significance between two groups was accomplished using Student's t-test. One-way analysis of variance was used for multiple-group comparison. P Ͻ.05 was considered statistically significant.
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Results
Mutation analysis and clinical data
We molecularly interrogated KCND3 in 86 unrelated genotype-negative/phenotype-positive patients with a referral diagnosis of BrS who had been previously analyzed for mutations in the eight known BrS-susceptibility genes. Overall, 96% of patients were of Caucasian descent, 84% were male, the average age at diagnosis was 45 Ϯ 14 years, and 34% exhibited a spontaneous type I Brugada ECG pattern. Comprehensive mutational analysis of KCND3 yielded two putative pathogenic mutations in two genetically elusive BrS cases.
Abnormal DHPLC elution profiles ( Figure 1A ) and subsequent direct DNA sequencing ( Figure 1B ) led to the identification of a KCND3 c.348 C¡T nucleotide substitution and a KCND3 c.1798 G¡C nucleotide substitution in two distinct genetically elusive BrS cases, which resulted in a L450F missense mutation (lysine [L] for phenylalanine
[F] at position 450) and G600R missense mutation (glycine [G] for arginine [R] at position 600), respectively. Both the L450F and G600R missense mutations were absent from 1,560 reference alleles (P Ͻ.001) and involve highly conserved residues located in the Kv4.3 carboxyl (C)-terminus ( Figure 1C, 1D) . The L450F-and G600R-positive BrS index cases were genotype-negative for mutations in the eight known BrS-susceptibility genes.
In addition, the analysis of KCND3's seven translated exons in 780 ostensibly healthy controls revealed only two amino acid-altering genetic variants (K214R and T486A), suggesting that KCND3 harbors minimal background amino acid-altering genetic variation in comparison with other channelopathic genes.
The first BrS index case (Kv4.3-L450F) was a 45-yearold male with a history of heart palpitations at rest. No arrhythmias have been documented, but ST segment elevation in leads V 1 and V 2 of the patient's resting Holter ECG were suspicious for BrS. There was no documented history of syncope or cardiac events, and the patient's family history was negative. He underwent a flecainide test that induced a type 1 ECG pattern (Figure 2A) .
The second BrS index case (Kv4.3-G600R), a 22-yearold male with a history of heart palpitations and presyncope, was discovered unconscious and unresponsive in bed. While hospitalized, a 12-lead ECG revealed ST segment elevation in V 1 , V 2 , and V 3 and a QTc of 523 ms (data not shown). Cardiac enzymes were borderline normal, with a creatine kinase of 370, a troponin I of 0.32, and a relative index of 1.3. A complete cardiac workup including echocardiogram and coronary angiogram was performed and found to be normal. All drug/toxicology screens were negative.
A follow-up ECG several days later revealed downsloping ST segment elevation in the right precordial leads (V 1 -V 3 ) with a normal PR interval of 150 ms ( Figure 2B ). The patient's QT interval remained slightly prolonged. Given the patient's significant paternal family history of sudden cardiac death (paternal grandfather died suddenly at age 39 and a paternal uncle died suddenly at age 35) and the abnormal ECG findings suggestive of BrS, an internal cardiac defibrillator was implanted as a secondary prevention.
Heterologous expression and functional characterization of Kv4.3-L450F and Kv4.3-G600R
To recapitulate the I to current in vitro, Kv4.3-WT, Kv4.3-L450F, or Kv4.3-G600R was heterologously coexpressed with KChIP2-WT in HEK293 cells ( Figure 3A) . Analysis of the current-voltage relationship indicated that Kv4.3-L450F or Kv4.3-G600R plus KChIP2-WT significantly increased I to current density from 0 mV to ϩ40 mV (n ϭ 15 for both mutations, P Ͻ.05) compared with Kv4.3-WT plus KChIP2-WT (n ϭ 18, Figure 3B ). Kv4.3-L450F and Kv4.3-G600R significantly increased current density at 0 mV by 154.3% and 48.1% percent, respectively, from 46.6 Ϯ 4.6 (WT, n ϭ 18) to 118.5 Ϯ 16.0 (L450F, n ϭ 15, P Ͻ.05) and 69.0 Ϯ 10.6 (G600R, n ϭ 15, P Ͻ.05) and similarly increased the peak current density at 40 mV by 146.2% and 50.4%, respectively, from 166.6 Ϯ 14.8 (WT, n ϭ 18) to 410.2 Ϯ 51.4 (L450F, n ϭ 15, P Ͻ.05) and 250.5 Ϯ 34.2 (G600R, n ϭ 15, P Ͻ.05, Figure 3C ). Kv4.3-G600R plus KChIP2-WT exhibited significantly slower inactivation across the 0 -40 mV range compared with Kv4.3-WT plus KChIP2-WT from 71.9 Ϯ 4.5 ms (WT at 40 mV, n ϭ 18) to 89.3 Ϯ 3.0 ms (G600R at 40 mV, n ϭ 15, P Ͻ.05, Figure  4A ). Kv4.3-L450F plus KChIP2-WT significantly increased the I to total charge by 117.0% at 40 mV (n ϭ 15, P Ͻ.05), and Kv4.3-G600R plus KChIP2-WT significantly increased the I to total charge by 58.3% at 40 mV (n ϭ 15, P Ͻ.05) compared with Kv4.3-WT plus KChIP2-WT (n ϭ 18, Figure 4B) .
Kv4.3-L450F significantly shifted V 1/2 of inactivation Ϫ5.2 mV from Ϫ21 Ϯ 0.7 mV (WT, n ϭ 12) to Ϫ26.2 Ϯ 0.7 mV (L450F, n ϭ 7, P Ͻ.05, Figure 4C ), while the Kv4.3-G600R mutation did not significantly alter the inactivation kinetics of I to compared with Kv4.3-WT. The respective k (slope factor) remains unchanged for both mutations. The time constants for the recovery from inactivation, assessed using a two-pulse protocol (see inset Figure 4D and figure legend) were 57.4 Ϯ 1.7 ms for cells cotransfected with Kv4.3-WT plus KChIP2 (n ϭ 7), 55.2 Ϯ 1.6 ms for cells cotransfected with Kv4.3-L450F plus KChIP2 (n ϭ 5), and 61.6 Ϯ 1.8 ms for cells cotransfected with Kv4.3-G600R plus KChIP2 (n ϭ 6). There was no significant difference among the three groups.
Simulated effect of Kv4.3-L450F and Kv4.3-G600R on the RV epicardial AP
To simulate the experimentally observed effects of the L450F and G600R mutations on the RV AP, a modified Luo-Rudy II AP model was used as described elsewhere. 16 Simulated I to traces under standard voltage-clamp conditions during the step to 0 mV for 100 ms from a holding potential of Ϫ90 mV indicates that the heterozygous expression of Kv4.3-L450F or Kv4.3-G600R increases peak current by 72% and 25%, respectively, and that Kv4.3-G600R slows the inactivation time constant by 19.0% relative to WT ( Figure 5A ). These values closely recapitulate the properties expected to be associated with a 50% reduction in the experimentally obtained values for the Kv4.3-L450F and Kv4.3-G600R currents across the 0 mV to ϩ40 mV range. The total charge carried by the simulated I to current was increased 59% by L450F relative to WT and 29% by G600R relative to WT. This computer simulation was again similar to the experimentally observed values of 58.5% and 29.1% for L450F and G600R, respectively, that were derived from heterologous expression studies.
Simulated RV epicardial APs using Kv4.3-L450F, Kv4.3-G600R, and WT I to currents were used to assess the ability of the L450F and G600R mutants to cause the loss of the AP dome in the modified Luo-Rudy II AP model. After several cycles of simulation at a basic cycle length of 800 ms to allow for reequilibration of intracellular Ca2ϩ concentrations, the simulated AP containing either Kv4.3-L450F or Kv4.3-G600R mutant I to current yielded a marked and stable loss of the AP dome in comparison with Kv4.3-WT ( Figure 5B ).
Discussion
The role of the I to current remains central to "the repolarization disorder" theory of BrS. The use of RV canine wedge preparations over the past decade has elucidated the critical role of the intrinsic I to -mediated transmural voltage gradient in the inscription of the J wave under physiologic conditions 17 and the development of ST segment elevation and reentrant ventricular arrhythmias in the presence of potassium channel activators 18 and sodium and calcium channel blockers 19 that function to amplify the intrinsic I to gradient, resulting in the loss of the AP dome at some epicardial sites. Furthermore, the recording of monophasic APs of the RV outflow tract has demonstrated the presence of a prominent AP notch in the epicardium but not in the endocardium of patients with BrS, providing clinical evidence that an I to -mediated transmural gradient is present in humans. 20 Lastly, while sodium channel blockers have been shown to unmask or induce a type I BrS ECG pattern, the use of quinidine, a sodium channel blocker that also potently inhibits I to , has been demonstrated to normalize ST segment elevation 21 in patients with BrS, suggesting that the reduction of the I to current may have clinical relevance. Despite the growing body of evidence linking the I to current to the pathogenesis of BrS, until recently there was minimal experimental data to directly implicate perturbations in I to to disease. The identification of a BrS-associated loss-of-function missense mutation in KCNE3 provided the first evidence that mutations resulting in an increase in I to could produce a type I BrS ECG pattern. 10 Furthermore, canine wedge preparations treated with the I to -specific activator NS5806 increased the I to -mediated AP notch in the epicardium but not in the endocardium, leading to J-wave accentuation, development of phase 2 reentry, and the initiation of ventricular tachycardia in both ventricles providing further evidence that I to gain of function can recapitulate the hallmarks of BrS.
14 Consistent with the established role of I to in BrS pathogenesis, our present study demonstrates the first association of gain-of-function mutations in the KCND3-encoded Kv4.3 ␣-subunit that conducts I to in humans with BrS. Here we present two unrelated cases, one an asymptomatic 45-year-old male with documented ST segment elevation in the right precordial leads on Holter ECG and a positive flecainide test, and the second, a 22-year-old male with a documented type I BrS ECG pattern and a family history of sudden death who was discovered unresponsive in bed. Both were found to harbor novel missense mutations in KCND3. In addition, these mutations involved highly conserved residues in the Kv4.3 C-terminus and were both absent in 1,560 reference alleles. . C: Steady-state inactivation curves of Kv4.3-WT, Kv4.3-L450F, or Kv4.3-G600R with KChIP2 determined from a holding potential of Ϫ100 mV to prepulse of Ϫ5 mV in 5-mV increments with 0.5-second duration followed by a test pulse of ϩ20 mV with 0.5-second duration and fitted with a Boltzmann function. D: Recovery from inactivation of Kv4.3-WT, Kv4.3-L450F, or Kv4.3-G600R with KChIP2 determined from a holding potential of Ϫ80 mV to prepulse of ϩ20 mV with 0.5-second duration, with increased recovery interval, followed by a test pulse of ϩ20 mV with 500-ms duration and fitted with a one-exponential function. All values shown represent mean Ϯ SEM.
The heterologous coexpression of both Kv4.3-L450F and Kv4.3-G600R with KChIP2 resulted in a gain-of-function in the I to current. Further, simulations using a modified Luo-Rudy II AP model that incorporates an increase in I to maximal conductance (G Kv4.3 ) consistent with experimentally derived data (1.30, 1.56, and 2.32 mS/F for WT, G600R, and L450F, respectively) demonstrated that the 73.1% increase in I to current associated with Kv4.3-L450F and the modest 25.2% increase in I to current together with a 19% slowing of I to inactivation associated with Kv4.3-G600R are both capable of producing the stable loss of the AP dome in RV epicardial tissue.
Interestingly, simulations using the same modified LuoRudy II model that incorporates a smaller G Kv4.3 intended to model the LV epicardial AP (0.5 and 0.7 mS/F for WT and G600R, respectively) did not demonstrate loss of the AP dome. The use of a smaller wild-type G Kv4.3 (0.25 mS/F) that fails to fully reproduce the deep RV AP likely explains why a 3.5-fold acceleration of I Na inactivation and a sevenfold increase in G Kv4.3 (to 1.75 mS/F) were required to simulate the ionic basis of BrS in a previous study that used a Luo-Rudy II AP model. 16 By setting wild-type I to to a more physiologically relevant G Kv4.3 , the in silico modeling included in this study demonstrates that even the modest increase in I to that is expected to be associated with the heterozygous expression of Kv4.3-G600R in the heart is capable of causing the loss of the AP dome in the RV epicardium. While the role of the I to current in producing the characteristic "spike and dome" morphology of the epicardial AP is well established, the precise role of I to in regulating the AP duration (APD) in large mammals remains largely undefined. In both the Winslow-Rice-Jafri canine ventricular cell and the Luo-Rudy II multicellular fiber AP models, the effect of increased Kv4.3 current density on canine AP shape and duration demonstrates a bimodal phenomenon, whereby increasing I to current density in the presence of high baseline densities is predicted to shift the AP from a spike-and-dome morphology to a shortened AP that lacks the plateau phase. 22 Interestingly, in both models, increasing I to current density in the presence of low baseline densities is predicted to result in a modest prolongation of the APD. Based on both single-cell and multicellular AP modeling, the effect of I to perturbations appears to be largely dependent on the strength of the underlying I to current that the I to alterations are superimposed on.
Thus, one could envision a scenario wherein the roughly 73.1% and 25.2% increase in I to current density conferred by heterozygous expression of Kv4.3-L450F and Kv4.3-G600R, respectively, in the heart might be expected to increase APD in the LV where I to current density is relatively low, as was observed for Kv4.3-G600R (data not shown) and the I to activator NS5806, 14 resulting in a prolonged QT interval and the heterogeneous loss of the AP dome in RV epicardium where I to current densities are the highest. While this scenario certainly fits with the clinical and electrophysiological phenotype associated with Kv4.3-L450F and Kv4.3-G600R, drawing a definitive conclusion on the impact of I to gain-of-function mutations on the APD and thus QT interval based on existing modeling is complicated by the existing disagreement between various strand and single myocyte computational models in regards to the true role the I to current plays in determining cardiac APD. 23 Even though the exact effect of loss-and gain-of-function mutations in KCND3 on the APD and QT interval in humans is not thoroughly understood, prolongation of the QT interval in the presence of ST segment elevation appears to be a clinical hallmark in some BrS cases. 24 Thus, the presence of QT prolongation in the G600R-positive BrS index case is consistent with the clinical scenario of BrS and not necessarily an indication of an additional underlying channelopathy such as LQTS. The functional investigation of rare mutations in the KCND3 may provide an important opportunity to deepen our understanding of the physiologic and pathophysiologic roles of the I to current in shaping the human cardiac AP.
Given the modest increase in I to current associated with Kv4.3-L450F and Kv4.3-G600R, we speculate that the gain-of-function mutations in KCND3 may leave affected individuals susceptible to modest physiologic changes in the inward (I Na and I L,Ca ) or outward (I to and I K-ATP ) currents active during early repolarization. An increase in vagal tone during sleep or the activation of epicardial predominant I K-ATP currents as a result of metabolic stress could further exacerbate the genetically enhanced I to -mediated transmural voltage gradient associated with Kv4.3-L450F or Kv4.3-G600R in the RV epicardium, pushing the AP to more negative potentials and resulting in the failure of the L-type calcium channel to activate and the heterogenous loss of AP dome at some epicardial sites. 9 Due to higher baseline levels of I to expression in the RV epicardium of males compared with females, 25 males harboring I to gain-of-function mutations are likely more sensitive to physiologic changes that can precipitate the arrhythmic manifestations of BrS than females, thus the identification of Kv4.3-L450F and Kv4.3-G600R in two male BrS index cases is not surprising.
The discovery of rare BrS-associated I to gain-of-function mutations in KCND3 supports the hypothesis that a genetically enhanced transmural dispersion of repolarization in the RV may directly contribute to BrS pathogenesis. Given that loss-of-function mutations in Nav1.5-interacting proteins as well as in the Cav1.2-interacting proteins may contribute to electrocardiographic and arrhythmogenic manifestations of BrS by exposing a large unopposed I to current in the RV epicardium, it stands to reason that mutations in genes encoding Kv4.3-interacting proteins or genetic regulators of KCND3 expression that enhance the I to -mediated transmural voltage gradient could function as novel pathogenic substrates for BrS. Further interrogation of the Kv4.3 macromolecular complex and regulators of KCND3 expression is needed to elucidate the role of the I to current in the pathogenesis of BrS and other J-wave syndromes.
Conclusion
In conclusion, this study provides the molecular and functional evidence necessary to implicate KCND3 as a novel BrS-susceptibility gene (KCND3-BrS or BrS9). Further studies are warranted to fully elucidate the mechanisms responsible for the increase in I to current observed with Kv4.3-L450F and Kv4.3-G600R and the full extent to which rare I to gain-of-function mutations contribute to BrS pathogenesis.
